pharma · Malaria · Pharmacokinetics · CNSP
CNS Pharmaceuticals
CNS Pharmaceuticals clinical programs — 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Houston, TX 77027, US
- Founded
- 2017
- Employees
- 12
- Programs
- 21
- Drugs
- 18
- Patents
- 0
CNS Pharmaceuticals projects
11 ClinicalTrials.gov programs sponsored by CNS Pharmaceuticals.
CNS Pharmaceuticals has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
9941
CNS Pharmaceuticals
Menopause
1 trial -
Berubicin
CNS Pharmaceuticals
Glioblastoma Multiforme, Adult
1 trial -
Berubicin hydrochloride, Cecenu® 40 mg Kapsel
CNS Pharmaceuticals
Glioblastoma multiforme (GBM)
1 trial -
CTX-4430
CNS Pharmaceuticals
Acne Vulgaris
1 trial -
DSM265
CNS Pharmaceuticals
Malaria
2 trials -
MMV390048 40mg
CNS Pharmaceuticals
Malaria
1 trial -
OZ439
CNS Pharmaceuticals
Malaria
1 trial -
Paclitaxel
CNS Pharmaceuticals
Ovarian Cancer
1 trial -
Sertraline+Antibiotic (penicillin/azithromycin)
CNS Pharmaceuticals
Pandas
1 trial -
rTMS (repetitive transcranial magnetic stimulation)
CNS Pharmaceuticals
Obsessive-Compulsive Disorder
1 trial -
vitamin C
CNS Pharmaceuticals
Ovarian Cancer
1 trial
Frequently asked questions
How many clinical projects does CNS Pharmaceuticals have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.